

Dirk Spitzer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9071771/publications.pdf>

Version: 2024-02-01

19
papers

397
citations

759233

12
h-index

794594

19
g-index

20
all docs

20
docs citations

20
times ranked

567
citing authors

#	ARTICLE	IF	CITATIONS
1	The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer. <i>BMC Cancer</i> , 2022, 22, 263.	2.6	3
2	Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102. <i>Clinical Cancer Research</i> , 2022, 28, 3573-3589.	7.0	12
3	Preclinical Evaluation of an Engineered Single-Chain Fragment Variable-Fragment Crystallizable Targeting Human CD44. <i>Journal of Nuclear Medicine</i> , 2021, 62, 137-143.	5.0	13
4	Multifunctional thiosemicarbazones and deconstructed analogues as a strategy to study the involvement of metal chelation, Sigma-2 (σ_2) receptor and P-gp protein in the cytotoxic action: In vitro and in vivo activity in pancreatic tumors. <i>European Journal of Medicinal Chemistry</i> , 2018, 144, 359-371.	5.5	33
5	Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochondrial superoxide production and caspase activation in pancreatic cancer. <i>BMC Cancer</i> , 2017, 17, 51.	2.6	37
6	The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 14.	8.6	8
7	Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer. <i>PLoS ONE</i> , 2017, 12, e0190125.	2.5	14
8	Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology. <i>Scientific Reports</i> , 2016, 6, 22661.	3.3	6
9	Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane. <i>Oncotarget</i> , 2016, 7, 31534-31549.	1.8	12
10	Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic. <i>Oncotarget</i> , 2016, 7, 33529-33541.	1.8	21
11	Incorporation of Porcine Adenovirus 4 Fiber Protein Enhances Infectivity of Adenovirus Vector on Dendritic Cells: Implications for Immune-Mediated Cancer Therapy. <i>PLoS ONE</i> , 2015, 10, e0125851.	2.5	7
12	Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer. <i>Molecular Cancer</i> , 2014, 13, 50.	19.2	24
13	Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. <i>Molecular Oncology</i> , 2014, 8, 956-967.	4.6	38
14	Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3. <i>BMC Cancer</i> , 2014, 14, 35.	2.6	27
15	Use of Multifunctional Sigma-2 Receptor Ligand Conjugates to Trigger Cancer-Selective Cell Death Signaling. <i>Cancer Research</i> , 2012, 72, 201-209.	0.9	41
16	A Genetically Encoded Multifunctional TRAIL Trimer Facilitates Cell-Specific Targeting and Tumor Cell Killing. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2142-2151.	4.1	19
17	Cutting Edge: Treatment of Complement Regulatory Protein Deficiency by Retroviral In Vivo Gene Therapy. <i>Journal of Immunology</i> , 2006, 177, 4953-4956.	0.8	13
18	In Vivo Correction of Complement Regulatory Protein Deficiency with an Inhibitor Targeting the Red Blood Cell Membrane. <i>Journal of Immunology</i> , 2005, 175, 7763-7770.	0.8	20

#	ARTICLE	IF	CITATIONS
19	ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement. <i>Molecular Immunology</i> , 2004, 40, 911-919.	2.2	49